EMD Chemicals, a subsidiary of Merck KGaA, and Epitome Biosystems, report that EMD launched WideScreen™ EpiTag™ ERK Pathway Assays, the first wave of bead-based, multiplex assays using EpiTag™ technology licensed from Epitome.

“The new line of assays will enable researchers to make quantitative, highly multiplexed measurements of important cell targets, greatly facilitating drug discovery efforts,” claims Lisa Johnson, Novagen and Calbiochem Business Unit Manager with EMD.

Next articleUMMZ Periodical Cicada Page